GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (NAS:IART) » Definitions » Equity-to-Asset

IART (Integra Lifesciences Holdings) Equity-to-Asset : 0.37 (As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Integra Lifesciences Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Integra Lifesciences Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $1,522 Mil. Integra Lifesciences Holdings's Total Assets for the quarter that ended in Sep. 2024 was $4,066 Mil. Therefore, Integra Lifesciences Holdings's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.37.

The historical rank and industry rank for Integra Lifesciences Holdings's Equity-to-Asset or its related term are showing as below:

IART' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3   Med: 0.43   Max: 0.46
Current: 0.37

During the past 13 years, the highest Equity to Asset Ratio of Integra Lifesciences Holdings was 0.46. The lowest was 0.30. And the median was 0.43.

IART's Equity-to-Asset is ranked worse than
78.92% of 868 companies
in the Medical Devices & Instruments industry
Industry Median: 0.64 vs IART: 0.37

Integra Lifesciences Holdings Equity-to-Asset Historical Data

The historical data trend for Integra Lifesciences Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings Equity-to-Asset Chart

Integra Lifesciences Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.42 0.45 0.46 0.42

Integra Lifesciences Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.42 0.39 0.38 0.37

Competitive Comparison of Integra Lifesciences Holdings's Equity-to-Asset

For the Medical Devices subindustry, Integra Lifesciences Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integra Lifesciences Holdings's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's Equity-to-Asset falls into.



Integra Lifesciences Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Integra Lifesciences Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1587.884/3781.988
=0.42

Integra Lifesciences Holdings's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=1521.587/4065.803
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Integra Lifesciences Holdings  (NAS:IART) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Integra Lifesciences Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Integra Lifesciences Holdings Business Description

Traded in Other Exchanges
Address
1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Executives
Eric Schwartz officer: Corp VP, Gen Counsel & Sec C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103
Michael J. Mcbreen officer: Executive VP & President, CSS 1100 CAMPUS ROAD, PRINCETON NJ 08540
Jeffrey Mosebrook officer: SVP, Fin & PAO 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Stuart Essig director, officer: President and CEO 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Barbara B Hill director
Davis Robert T. Jr. officer: Corp VP, Pres. Neurosurgery INTEGRA LIFESCIENCES CORPORATION, 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Chantal Veillon-berteloot officer: EVP & CHRO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Lea Daniels Knight officer: EVP & CFO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Witte Jan De director, officer: President & CEO C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Harvinder Singh officer: Exec VP & PRES, International 1100 CAMPUS ROAD, PRINCETON NJ 08540
Lisa Evoli officer: Chief Human Resources Officer 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond G. Murphy director 14604 CARROLTON ROAD, ROCKVILLE MD 20853
Renee Wonlai Lo director 1100 CAMPUS ROAD, PRINCETON NJ 08540
Glenn Coleman officer: CVP, CHIEF FINANCIAL OFFICER C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Tru St Partnership, L.p. 10 percent owner 795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085